Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-09
2011-08-09
Cordero Garcia, Marcela M (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S004900
Reexamination Certificate
active
07994119
ABSTRACT:
This invention relates generally to peptides including tripeptides and to methods for pharmaceutical treatment of mammals using such tripeptides and analogs thereof. More specifically, the invention is directed to neuropeptide Y (“NPY”) receptor antagonists and agonists including O-glycosylated tripeptides, i.e. O-glycopeptides, and extended tripeptides, and their analogs, as well as to PYY analogs, to pharmaceutical compositions containing such tripeptides and PYY analogs, and to methods of treatment of mammals using such tripeptides and PYY analogs. In addition, the invention relates to methods of treatment of mammals using such tripeptides and PYY analogs for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm.
REFERENCES:
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 6962902 (2005-11-01), Balasubramanium et al.
patent: 7465710 (2008-12-01), Balasubramanium et al.
patent: 2006/0009395 (2006-01-01), Balasubramaniam et al.
patent: 2007/0197445 (2007-08-01), Balasubramaniam
patent: 2009/0227519 (2009-09-01), Balasubramaniam
Beechanahalli et al. Convenient high yield and stereoselective synthesis of O-glycopeptides using N-alpha-Fmoc-Tyr/Ser[Beta-D-Glc(OAc)4]OPfp generated in solution. Tetrahedron Letters 2004, 45, pp. 355-358.
Parker et al. Neuropeptide Y receptors as targets for anti-obesity drug develpment: prespective and current status. European Journal of Pharmacology. 2002. vol. 440, pp. 173-187.
H.J.C. Berendsen. A Glimpse of the Holy Grail? Science (1998) 282, pp. 642-643.
Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) 1-7.
Sigma. Designing Custom Peptides. http://www.sigma-genosys.com/peptide—design.asp (Accessed Dec. 16, 2004), 2 pages.
W.S. Messer, “Vasopressin and Oxytocin”, web document updated Apr. 3, 2000; http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm; 5 pages.
D.E. Smilek, et al. Proc. Natl. Acad. Sci. USA (1991) 88, pp. 9633-9637.
D. Voet and J.G. Voet. Biochemistry, 2nd Edition.(1995), pp. 235-241.
Sandgren et al. Nuclear Targeting of Macromolecular Polyanions by an HIV-Tat Derived Peptide. The Journal of Biological Chemistry. 2002. vol. 277, No. 41, pp. 38877-38883.
Kirby, D.A. et al., Neuropeptide Y: Y1 and Y2 Affinities of the Complete Series of Analogues with Single D-Residue Substitutions, J. Med. Chem., 1993, 36:3802-8.
Kirby, D.A. et al., Identification of High-Potency Neuropeptide Y Analogues through Systematic Lactamization, J. Med. Chem., 1997, 40:210-5.
Feinstein, R.D. et al., Structural Requirements for Neuropeptide Y18-36-Evoked Hypotension: A Systematic Study, J. Med. Chem., 1992, 35:2836-43.
Beck-Sickinger, A.G. et al., Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations, Biochem., 1994, 225:947-58.
Cox, H.M. et al., Structure-activity relationships with neuropeptide Y analogues: a comparison of human Y1-, Y2- and rat Y2-like systems, Regul. Pept., 1998, 75-76:3-8.
Mullins, D. et al., Identification of Potent and Selective Neuropeptide Y Y1 Receptor Agonists with Orexigenic Activity in Vivo, Mol. Pharmacol., 2001, 60:534-40.
Cordero Garcia Marcela M
University of Cincinnati
Wood Herron & Evans LLP
LandOfFree
Compounds for control of appetite does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for control of appetite, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for control of appetite will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2787195